An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C

• Status: Completed
• Trial end date: 2015-12-02

Summary

The purpose of the study is to demonstrate the noninferiority of Algeron in combination with ribavirin compared to Pegasys in combination with ribavirin in the treatment of chronic hepatitis C.

• Phase: Phase 3

Details

• Lead Sponsor: Biocad
• Treatments: Interferon-alpha; Peginterferon alfa-2a